Story Summary: aThis recent patent issuance strengthens and validates our strategy of establishing a broad and integrated IP portfolio upon which the company is building its microRNA-based diagnostic and therapeutic discovery engines. Many of these applications protect the specific microRNAs used in the companyas products. In addition, the company is pursuing more than 50 patent applications to protect methods of detecting microRNAs and methods of diagnosing and treating diseases with microRNAs. About microRNAsMicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. About miRviewaC/ ProductsmiRviewaC/ are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRviewaC/ mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP). miRviewaC/ squamous accurately identifies the squamous subtype of non small cell lung cancer (NSCLC), which carries an increased risk of severe of fatal internal bleeding and poor response to treatment for certain therapies. miRviewaC/ squamous accurately identifies the squamous subtype of non small cell lung cancer (NSCLC), which carries an increased risk of severe of fatal internal bleeding and poor response to treatment for certain therapies. About Rosetta GenomicsRosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-based molecular diagnostics. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The companyas first three microRNA-based tests, miRviewaC/ squamous, miRviewaC/ mets, and miRviewaC/ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of Wall Street Journalas Technology Innovation Awards in the medical/biotech category. rosettagenomics. In addition, any forward-looking statements represent Rosettaas views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date….Read the Full Story

Related posts:

1. Rosetta Genomics Announces Issuance of Three U.S. Patents
2. Prometheus puts $8m into Rosetta – Haaretz – Israel News
3. Mesothelioma Diagnostic Test Rights Granted to Pharmaceutical Company – Asbestos.com
4. Alnylam Joins GSK in Donating Intellectual Property to Patent Pool for Neglected Tropical Diseases
5. MicroRNA in Human Saliva May Help Diagnose Oral Cancer